Diacerein

Drug Profile

Diacerein

Alternative Names: Art 50; Artrodar; Artrolyt; Cartivix; Diacerhein; Diacetylrhein; Fisiodar; Galaxdar; KW 4800; Matrix; Rhein diacetate; SF 277; Verboril

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Istituto Gentili; Proter
  • Developer Abiogen Pharma; Ecupharma; Faran; Istituto Gentili; Kyowa Hakko; Lacer; Myungmoon Pharm; Neo-Farmaceutica; Proter; TRB Pharma; Wockhardt
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 10 Feb 2016 TRB Chemedica International plans the phase III/IV DISSCO trial for Osteoarthritis (In adults, In the elderly) in Canada, Spain, Austria and Czech Republic (PO) (NCT02688400)
  • 07 Mar 2014 Pharmacovigilance Risk Assessment Committee recommends restrictions of diacerein availability in Osteoarthritis to manage risk of adverse events in the European Union
  • 04 Mar 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top